Strategic leadership Upcoming leadership transition at Foundation Medicine with an interim CEO starting Aug 1, 2026 and ongoing search for a permanent successor. This leadership change represents an opportunity to engage stakeholders around continuity plans, strategic priorities in precision oncology, and potential realignment of partnerships and investment in diagnostic solutions.

Expansion & partnerships Active collaboration with Bristol Myers Squibb to develop MTAP biomarker tests and a CDx for MTAP deletion, expanding Foundation Medicine’s role in companion diagnostics and targeted therapies. This signals a strong avenue to propose expanded CDx capabilities, assay panels, and real-world data integration to support co-developed treatments.

Advanced diagnostics Development of FoundationOne CDx for MTAP deletion and MTAP biomarker tests indicates a focus on next generation sequencing based companion diagnostics and targeted biomarker strategies. Sales opportunities exist in expanding sequencing panels, assay sensitivity, and regulatory-grade diagnostics across multiple cancer indications.

Strategic acquisition Acquisition of Saga Diagnostics AB positions Foundation Medicine to broaden capabilities in diagnostic services, potential data assets, and geographic reach. This creates cross-sell opportunities for integrated testing platforms, expanded assay offerings, and enhanced biopharma collaboration potential.

Scale & financials Revenue in the high hundreds of millions to billions range with sizable funding, indicating robust demand for precision diagnostics and real world data solutions. Focus sales on large biopharma partnerships, expanded real-world evidence offerings, and enterprise-level diagnostic contracts to accelerate adoption.